3-(3-Cyclopropylmethoxy-4-difluoromethoxy-phenyl)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-hydroxy-propionamide | 725256-74-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 3-(3-Cyclopropylmethoxy-4-difluoromethoxy-phenyl)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-hydroxy-propionamide
• 英文别名: 3-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-3-(1,3-dioxoisoindol-2-yl)-N-hydroxypropanamide
• CAS: 725256-74-6
• 化学式: C₂₂H₂₀F₂N₂O₆
• 分子量: 446.407
• InChiKey: BBETXSAMADLPQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-(3-Cyclopropylmethoxy-4-difluoromethoxy-phenyl)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionic acid 、 N,N'-羰基二咪唑 、 盐酸羟胺 、 水 在 四氢呋喃 、 碳酸氢钠 、 水 、 Brine 、 magnesium sulfate 、 silica gel 、 乙酸乙酯 、 正己烷 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 以to give 3-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-hydroxy-propionamide as a white solid (700 mg, 61%)的产率得到3-(3-Cyclopropylmethoxy-4-difluoromethoxy-phenyl)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-hydroxy-propionamide
  参考文献：
  名称：

  Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses

  摘要：

  该发明涵盖了新型化合物、药学上可接受的盐、水合物、溶剂物、包合物、对映体、非对映异构体、外消旋体或其立体异构物混合物，这些化合物的制药组合物，以及在哺乳动物中治疗或预防与PDE4相关的疾病的方法。

  公开号：

  US07504427B2

文献信息

• FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
  申请人：MULLER George W.

  公开号：US20110124645A1

  公开（公告）日：2011-05-26

  The invention encompasses novel compounds, pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions in mammals for treatment or prevention of diseases associated with PDE4.

  该发明涵盖了新型化合物、药用盐、水合物、溶剂合物、笼合物、对映体、非对映体、混合物或其立体异构体的混合物，这些化合物的药物组成物以及在哺乳动物中用于治疗或预防与PDE4相关疾病的方法。
• Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
  申请人：CELGENE CORPORATION

  公开号：EP2036553A1

  公开（公告）日：2009-03-18

  Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本文公开了治疗、预防、改变和控制各种类型疼痛的方法。具体方法包括施用选择性细胞因子抑制药物或其药学上可接受的盐、溶液剂、水合物、立体异构体、凝胶体或原药，单独或与第二种活性剂和/或手术、心理或物理疗法联合使用。此外，还公开了适用于本发明方法的药物组合物、单一单位剂型和试剂盒。
• Compositions for treatment of cancers
  申请人：CELGENE CORPORATION

  公开号：EP2258363A1

  公开（公告）日：2010-12-08

  Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本研究公开了治疗、预防和/或控制癌症以及与不良血管生成有关或以不良血管生成为特征的疾病和失调的方法。具体方法包括单独施用选择性细胞因子抑制药物或与第二种活性成分联合施用。本发明还涉及减少或避免与化疗、放疗、激素治疗、生物治疗或免疫治疗相关的不良副作用的方法，其中包括施用选择性细胞因子抑制药物。本发明还公开了适用于本发明方法的药物组合物、单一单位剂型和试剂盒。
• Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
  申请人：——

  公开号：US20040091454A1

  公开（公告）日：2004-05-13

  Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本文公开了治疗、预防和/或控制黄斑变性的方法。具体的实施方案包括单独或与第二种活性剂和/或手术联合使用选择性细胞因子抑制药物或其药学上可接受的盐、溶液、水合物、立体异构体、凝胶体或原药。此外，还公开了适用于本发明方法的药物组合物、单一单位剂型和试剂盒。
• Modulation of stem and progenitor cell differentiation, assays, and uses thereof
  申请人：Hariri J. Robert

  公开号：US20050118715A1

  公开（公告）日：2005-06-02

  The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention relates to the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.

  本发明涉及调节哺乳动物干细胞和祖细胞分化的方法。本发明的方法可用于调节和控制哺乳动物，特别是人类干细胞沿特定细胞和组织系的分化和成熟。本发明的方法涉及使用某些有机小分子来调节干细胞或祖细胞群沿特定细胞系和组织系的分化，特别是源自产后胎盘的胚胎样干细胞的分化或早期祖细胞向粒细胞系的分化。最后，本发明涉及在移植和其他医疗中使用这种分化的干细胞或祖细胞。